Core Viewpoint - The recent rebound in the CXO sector is not indicative of a comprehensive recovery but rather a reaction to easily confirmable short-term improvements, particularly among domestic demand-driven CRO and experimental service companies, while leading CDMO companies focused on external demand have underperformed [3][4][5]. Market Dynamics - The market is currently trading based on short-term rebounds rather than a long-term recovery in the CXO industry, with a notable divergence in performance between domestic-focused companies and those reliant on global demand [4][5]. - Despite an overall positive sentiment in the industry, caution remains regarding CDMO companies, which are facing complex pricing environments and geopolitical uncertainties that could impact long-term growth [5][12]. Financial Performance - WuXi AppTec's 2025 performance forecast indicates a revenue of approximately 454.56 billion RMB, a year-on-year increase of about 15.84%, and a net profit of around 191.51 billion RMB, reflecting a significant growth of 102.65% [7]. - The company's revenue growth trajectory has shown consistent improvement throughout the year, with a core business revenue increase of approximately 21.40%, indicating enhanced growth momentum post-divestiture of certain business segments [9][10]. Market Sentiment and Valuation - The market's cautious stance towards CDMO companies is driven by uncertainties regarding future growth, particularly in relation to geopolitical risks and the sustainability of demand for emerging business lines like TIDES [12][13]. - The valuation of CDMO companies reflects a conservative outlook on long-term growth potential rather than immediate revenue uncertainties, leading to a disconnect between fundamental recovery and stock price performance [10][28]. Structural Changes in the Industry - The growth in WuXi AppTec's small molecule D&M business is attributed to an expansion in order structure and capabilities, moving beyond traditional roles to encompass more complex production processes [20][22]. - The acquisition of Dongyao Pharmaceutical by WuXi AppTec highlights a strategic move to secure capacity in a high-demand sector, emphasizing the importance of time as a critical resource in the competitive landscape [24][26]. Conclusion - The current rebound in the CXO sector appears to be driven by emotional and anticipatory factors rather than a full reassessment of long-term industry value, with a clear distinction between domestic and external demand dynamics [28][29].

研究报告 Research Report 9 Feb 2026 香港医疗 Hong Kong Health Care 医药行业周报（2026.02.02-2026.02.06）：市场情绪回暖；看好基本面表现强劲的创新药产业链龙头 Healthcare Weekly (2026.02.02-2026.02.06): Market Sentiment Warms; Bullish on Leaders in Innovative Drug Chain with Strong Fundamentals [Table_yemei1] 观点聚焦 Investment Focus | [Table_Info] | | | | | --- | --- | --- | --- | | 股票名称 | 评级 | 股票名称 | 评级 | | 百济神州 | Outperform 华润医药 | | Outperform | | 京东健康 | Outperform 国药控股 | | Neutral | | 药明生物 | Outperform 映恩生物 | | Outperform | | 信达生物 | Outperform 金斯瑞生物科 ...

Group 1: Market Overview - The Hong Kong pharmaceutical sector showed significant recovery on February 6, with innovative drugs experiencing a rebound, particularly the Hong Kong Stock Connect Innovative Drug ETF (520880), which rose by nearly 2% after opening lower [1][8] - Notable stocks included Nocera Health, which surged over 12%, projecting revenues of 2.37 billion yuan for 2025, a year-on-year increase of approximately 134%, and an expected net profit of around 630 million yuan, marking its first profit [1][8] Group 2: Company Performance - Companies such as Rongchang Biopharmaceutical and CanSino Biologics also reported profitability, with net profit forecasts exceeding 100% year-on-year growth [1][8] - Ark Health announced a profit forecast of 7 to 10 million yuan for 2025, indicating a turnaround from losses, and raised approximately 144.3 million HKD to accelerate the development of its AI-driven chronic disease management platform [3][10] Group 3: ETF Insights - The Hong Kong Stock Connect Innovative Drug ETF (520880) and the Hong Kong Stock Connect Medical ETF (159137) are highlighted as effective investment vehicles, with the former focusing entirely on innovative drug development companies, where the top ten weighted stocks account for over 73% [6][12] - The Hong Kong Stock Connect Medical ETF (159137) has shown strong performance, with 9 out of 10 disclosed component stocks expected to report profits, and several companies projected to double their net profits year-on-year [3][10]

Investment Rating - The report maintains a "Buy" rating for the medical services industry, suggesting a positive outlook for investment opportunities in this sector [10][64]. Core Insights - The medical services sector has shown resilience, with a recent increase in the sector's PE ratio to 34.43X and PB ratio to 3.49X, indicating a positive trend in valuation metrics [4][29]. - The approval of internet medical first diagnosis trials in Beijing marks a significant regulatory breakthrough, potentially accelerating the online medical service process and providing new market opportunities for private medical institutions [5][62][63]. - The report highlights the importance of digital regulation and standardization in enhancing service capabilities for private medical institutions, particularly in consumer healthcare sectors like pediatrics and dermatology [5][62]. Summary by Sections Industry Performance - The pharmaceutical and biological sector increased by 0.14%, ranking 15th among 31 primary industries, outperforming the Shanghai Composite Index by 1.47 percentage points [2][12]. - The medical services sub-sector reported a 1.31% increase, closing at 6827.17 points, with a year-to-date performance of 41.41% [24][27]. Company Performance - Top-performing companies in the medical services sector include Meidisi (+18.0%), Tongce Medical (+8.1%), and Nuosige (+5.7%), while underperformers include Haoyuan Pharmaceutical (-6.2%) and Baicheng Pharmaceutical (-4.5%) [3][27]. Valuation Metrics - The medical services sector's PE ratio has increased by 0.56X from the previous week, while the PB ratio has risen by 0.06X, indicating a strengthening in market confidence [4][29]. Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and peptide CDMO in the pharmaceutical outsourcing sector, as well as companies like WuXi AppTec and Haoyuan Pharmaceutical [10][64]. - It also recommends monitoring private medical service providers with compliance experience, such as Aier Eye Hospital, as they are expected to benefit from the evolving regulatory landscape [5][64].

Group 1: US Pharmaceutical Earnings Season - Eli Lilly reported Q4 revenue of $19.3 billion, a 43% year-over-year increase, with non-GAAP EPS of $7.54, up 42%. The weight loss drug Zepbound has surpassed Novo Nordisk's Wegovy in prescriptions, and the 2026 revenue guidance is set at $80-83 billion, exceeding market expectations with a projected growth of 27% [1][10]. - Novo Nordisk's sales for semaglutide (Ozempic/Wegovy) are expected to reach $34.608 billion in 2025, accounting for 73.9% of total revenue. In China, Ozempic's sales are approximately ¥5.932 billion, while Wegovy's are about ¥874 million. The oral version of Wegovy is set to launch in the US on January 5, 2026, with around 50,000 prescriptions within the first month [2][10]. - Merck's Keytruda achieved annual sales of $31.68 billion, a 7% increase, nearing 50% of total revenue. The new pulmonary hypertension drug Winrevair generated $1.443 billion in sales, more than tripling from 2024 [4][10]. - Johnson & Johnson's Q4 revenue was $24.56 billion, exceeding expectations, with a 10% increase in the innovative pharmaceuticals segment. The 2026 revenue guidance is set at $99.5-100.5 billion, also above expectations [6][10]. - Pfizer's Q4 revenue was $17.6 billion, with a 9% increase excluding COVID products. The 2026 revenue guidance is conservative at $59.5-62.5 billion, reflecting declines in COVID product sales and patent expirations [7][10]. - Sanofi's Q4 earnings exceeded expectations, with record sales of Dupixent reaching €4.246 billion, a 32.2% year-over-year increase [8][10]. Group 2: Industry Trends and Insights - The current earnings season indicates that in the innovative-driven pharmaceutical industry, there are no eternal leaders, only continuous evolution [9][10]. - The competition in the GLP-1 drug market has intensified, with Eli Lilly's tirzepatide overtaking Novo Nordisk's semaglutide, marking a new phase in the industry [10]. - The slowdown in sales growth for Merck's Keytruda, despite record sales, highlights the need for new products and acquisitions to navigate the post-Keytruda era [10]. - The focus of competition is shifting from injectable to oral formulations, as seen with Novo Nordisk's oral Wegovy and Eli Lilly's multi-target drug Retatrutide, to build product moats [10]. - Price competition and pipeline iteration will be key observation points, with the impact of US drug pricing legislation becoming evident and the onset of a "price war" among GLP-1 drugs [10]. Group 3: Hong Kong Pharmaceutical Sector Opportunities - The Hong Kong pharmaceutical sector has seen significant changes, with innovation drugs remaining the strongest growth engine, shifting from "signing" to "realization" of value [11][12]. - The medical device sector is experiencing a "double recovery" opportunity as the impact of centralized procurement policies diminishes, leading to performance and valuation recovery [13][14]. - The Chinese traditional medicine sector is active, driven by favorable policies, but there is a "temperature difference" between policy drivers and fundamental performance, necessitating careful selection of stocks [17][19]. Group 4: ETF Configuration and Strategy - Valuations in the Hong Kong medical sector remain attractive, with the latest PE ratio at 30.77x, still low compared to the past five years [18][19]. - Macro liquidity conditions are favorable, with expectations of RMB appreciation and stable HKD attracting funds to Hong Kong stocks [18][19]. - The upcoming National People's Congress in March will clarify annual growth targets and industry policy priorities, serving as a critical point for risk appetite re-evaluation [18][19].

Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].

证券之星消息，2月6日，生物经济（970038）指数报收于2177.69点，跌0.42%，成交181.33亿元，换手 率1.61%。当日该指数成份股中，上涨的有15家，泰格医药以3.06%的涨幅领涨，下跌的有34家，华兰 疫苗以3.48%的跌幅领跌。 生物经济（970038）指数十大成份股详情如下： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 资金流向方面，生物经济（970038）指数成份股当日主力资金净流出合计4.84亿元，游资资金净流入合 计1.18亿元，散户资金净流入合计3.66亿元。成份股资金流向详情见下表： ...

Core Viewpoint - The ChiNext Medical Index (970082) closed at 3882.75 points, down 0.63%, with a trading volume of 14.157 billion yuan and a turnover rate of 2.13% on February 6 [1] Group 1: Index Performance - Among the index constituents, 22 stocks rose while 28 stocks fell, with Tigermed leading the gainers at 3.06% and Aier Eye Hospital leading the decliners at 3.82% [1] - The top ten constituents of the ChiNext Medical Index include Aier Eye Hospital (9.18% weight, latest price 11.07, -3.82% change) and Tigermed (8.52% weight, latest price 65.65, +3.06% change) [1] Group 2: Market Capitalization - The total market capitalization of Aier Eye Hospital is approximately 103.232 billion yuan, while Tigermed's market capitalization is around 56.526 billion yuan [1] - Other notable companies include Mindray Medical (229.746 billion yuan) and Kanglong Chemical (55.486 billion yuan) [1] Group 3: Capital Flow - The net outflow of main funds from the ChiNext Medical Index constituents totaled 604 million yuan, while retail investors saw a net inflow of 412 million yuan [1] - The detailed capital flow shows that Tigermed had a net inflow of 14.716 million yuan from main funds, while retail investors experienced a net outflow of 1.41 million yuan [2]

Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing a significant rebound, particularly in innovative drugs, with several companies reporting strong earnings forecasts and positive growth trends [1][8]. Group 1: Innovative Drug Sector - The Hong Kong Stock Connect Innovative Drug ETF (520880) saw a rise of nearly 2% after opening lower, indicating strong investor interest [1][8]. - Innovent Biologics (诺诚健华) led the gains with a rise of over 12%, projecting revenues of 2.37 billion yuan for 2025, a year-on-year increase of approximately 134%, and an expected net profit of around 630 million yuan, marking its first profit [1][8]. - Other companies like Rongchang Biopharmaceutical and CanSino Biologics also reported profitability, with net profit growth exceeding 100% year-on-year [1][8]. Group 2: Medical Sector - The medical sector is also showing positive momentum, with AI healthcare and CXO-related stocks active; Ark Health (方舟健客) led with a 4.71% increase [3][10]. - Ark Health forecasts a profit of 7 to 10 million yuan for 2025, indicating a turnaround from previous losses, and raised approximately 144.3 million HKD to accelerate the development of its AI-driven chronic disease management platform [3][10]. - Among the 10 component stocks of the Hong Kong Stock Connect Medical ETF (159137) that disclosed earnings forecasts, 9 are expected to be profitable, with several companies anticipating net profit growth of over 100% [3][10]. Group 3: Market Trends and Investment Opportunities - Despite the positive earnings outlook, the recent performance of the pharmaceutical sector has diverged from these fundamentals, with the Hong Kong Stock Connect Innovative Drug ETF (520880) experiencing four consecutive weeks of declines [5][12]. - The current market conditions may present a favorable opportunity for accumulation in the Hong Kong pharmaceutical sector, particularly through ETFs, which offer higher efficiency and flexibility [5][12]. - Investors are encouraged to consider the Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds for a comprehensive exposure to innovative drug companies, with the top ten holdings accounting for over 73% of the portfolio [6][12].

Group 1: Market Overview - The Hong Kong pharmaceutical sector showed significant recovery on February 6, with innovative drugs experiencing a rebound, particularly the Hong Kong Stock Connect Innovative Drug ETF (520880), which rose by nearly 2% after opening in the red [1] - Notable stocks included Nocera Biopharma, which surged over 12%, projecting revenues of 2.37 billion yuan for 2025, a year-on-year increase of approximately 134%, and an expected net profit of around 630 million yuan, marking its first profit [1] Group 2: Company Performance - Rongchang Biopharma and CanSino Biologics also reported profitability, with both companies forecasting net profit growth exceeding 100% year-on-year [1] - Ark Health announced a profit forecast of 7 to 10 million yuan for 2025, indicating a turnaround from losses, and raised approximately 144.3 million HKD to accelerate the development of its AI-driven chronic disease management platform [3] - Among the 10 component stocks of the Hong Kong Stock Connect Medical ETF (159137) that disclosed earnings forecasts, 9 are expected to report profits, with several companies like Zhaoyan New Drug, MicroPort Medical, and WuXi AppTec anticipating net profit growth of over 100% [3]